All In MedTech

FDA Clearance Tracker · P030019-S009

ORTHOVISC SODIUM HYALURONATE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2007 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 26, 2007

Approved

Time to decision

546 days

Received Apr 28, 2006. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P030019-S009
Device name
ORTHOVISC SODIUM HYALURONATE
Applicant location
Beford, MA
Received
Apr 28, 2006
Decided
Oct 26, 2007
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030019

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFYING THE MANUFACTURING PROCESS FOR ORTHOVISC TO ONE THAT PRODUCES SODIUM HYALURONATE FROM BACTERIAL FERMENTATION. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).

Source documents

Other decisions for Anika Therapeutics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.